{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:17:40Z","timestamp":1774865860477,"version":"3.50.1"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/yco.0b013e32835f6747","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T22:24:49Z","timestamp":1363991089000},"page":"276-282","source":"Crossref","is-referenced-by-count":21,"title":["Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease"],"prefix":"10.1097","volume":"26","author":[{"given":"Christoffer","family":"Ros\u00e9n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210206","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1474-4422(11)70072-2","article-title":"The projected effect of risk factor reduction on Alzheimers disease prevalence.","volume":"10","author":"Barnes","year":"2011","journal-title":"Lancet Neurol"},{"key":"R2-9-20210206","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: a Delphi consensus study.","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet"},{"key":"R3-9-20210206","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"R4-9-20210206","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"R5-9-20210206","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","article-title":"Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimers disease in the presenilin 1 E280A kindred: a case-control study.","volume":"11","author":"Reiman","year":"2012","journal-title":"Lancet Neurol"},{"key":"R6-9-20210206","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimers disease.","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"R7-9-20210206","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.1228541","article-title":"Preventing Alzheimers disease.","volume":"337","author":"Selkoe","year":"2012","journal-title":"Science"},{"key":"R8-9-20210206","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000311703","article-title":"Low incidence of postlumbar puncture headache in 1,089 consecutive memory clinic patients.","volume":"63","author":"Zetterberg","year":"2010","journal-title":"Eur Neurol"},{"key":"R9-9-20210206","first-page":"3","article-title":"About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson).","volume":"1","author":"Alzheimer","year":"1987","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"R10-9-20210206","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","article-title":"Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.","volume":"261","author":"Grundke-Iqbal","year":"1986","journal-title":"J Biol Chem"},{"key":"R11-9-20210206","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.1899488","article-title":"A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.","volume":"251","author":"Lee","year":"1991","journal-title":"Science"},{"key":"R12-9-20210206","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tins.2008.11.007","article-title":"Tau pathophysiology in neurodegeneration: a tangled issue.","volume":"32","author":"Spires-Jones","year":"2009","journal-title":"Trends Neurosci"},{"key":"R13-9-20210206","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimers disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"R14-9-20210206","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome.","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-9-20210206","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/j.1460-2075.1985.tb04000.x","article-title":"Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimers disease contain the same protein as the amyloid of plaque cores and blood vessels.","volume":"4","author":"Masters","year":"1985","journal-title":"EMBO J"},{"key":"R16-9-20210206","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/msj.20157","article-title":"Neuropathology of Alzheimers disease.","volume":"77","author":"Perl","year":"2010","journal-title":"Mt Sinai J Med"},{"key":"R17-9-20210206","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics.","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"R18-9-20210206","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(04)15441-X","article-title":"Imaging cerebral atrophy: normal ageing to Alzheimers disease.","volume":"363","author":"Fox","year":"2004","journal-title":"Lancet"},{"key":"R19-9-20210206","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1016\/j.neuropsychologia.2011.10.010","article-title":"The cortical neuroanatomy of neuropsychological deficits in mild cognitive impairment and Alzheimers disease: a surface-based morphometric analysis.","volume":"49","author":"Ahn","year":"2011","journal-title":"Neuropsychologia"},{"key":"R20-9-20210206","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1385\/MN:24:1-3:087","article-title":"CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimers disease.","volume":"24","author":"Blennow","year":"2001","journal-title":"Mol Neurobiol"},{"key":"R21-9-20210206","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","article-title":"Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.","volume":"297","author":"Hesse","year":"2001","journal-title":"Neurosci Lett"},{"key":"R22-9-20210206","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archneur.63.9.1277","article-title":"Neurochemical aftermath of amateur boxing.","volume":"63","author":"Zetterberg","year":"2006","journal-title":"Arch Neurol"},{"key":"R23-9-20210206","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/MAJ.0b013e3181e92a1f","article-title":"Elevated levels of tau protein in cerebrospinal fluid of patients with probable Creutzfeldt-Jakob disease.","volume":"340","author":"Wang","year":"2010","journal-title":"Am J Med Sci"},{"key":"R24-9-20210206","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF markers for incipient Alzheimers disease.","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet Neurol"},{"key":"R25-9-20210206","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2217\/bmm.09.83","article-title":"Cerebrospinal fluid biomarkers of Alzheimers disease.","volume":"4","author":"Fagan","year":"2010","journal-title":"Biomark Med"},{"issue":"Suppl 2","key":"R26-9-20210206","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00406-012-0362-3","article-title":"Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimers disease and other neurodegenerative dementias.","volume":"262","author":"Genius","year":"2012","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R27-9-20210206","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1212\/WNL.0b013e3182563bd0","article-title":"CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.","volume":"78","author":"Seppala","year":"2012","journal-title":"Neurology"},{"key":"R28-9-20210206","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimers disease.","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"R29-9-20210206","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","article-title":"CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.","volume":"60","author":"Strozyk","year":"2003","journal-title":"Neurology"},{"key":"R30-9-20210206","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/archneurol.2008.596","article-title":"Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.","volume":"66","author":"Tapiola","year":"2009","journal-title":"Arch Neurol"},{"key":"R31-9-20210206","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann Neurol"},{"key":"R32-9-20210206","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","article-title":"PET imaging of amyloid deposition in patients with mild cognitive impairment.","volume":"29","author":"Forsberg","year":"2008","journal-title":"Neurobiol Aging"},{"key":"R33-9-20210206","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.biopsych.2009.01.027","article-title":"Beta amyloid in Alzheimers disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.","volume":"65","author":"Grimmer","year":"2009","journal-title":"Biol Psychiatry"},{"key":"R34-9-20210206","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.","volume":"302","author":"Mattsson","year":"2009","journal-title":"JAMA"},{"key":"R35-9-20210206","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3233\/JAD-2011-101878","article-title":"Cerebrospinal fluid biomarkers for Alzheimers disease: diagnostic performance in a homogeneous mono-center population.","volume":"24","author":"Johansson","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"R36-9-20210206","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"R37-9-20210206","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.emboj.7600061","article-title":"Take five--BACE and the gamma-secretase quartet conduct Alzheimers amyloid beta-peptide generation.","volume":"23","author":"Haass","year":"2004","journal-title":"EMBO J"},{"key":"R38-9-20210206","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ana.20144","article-title":"Increased beta-Secretase activity in cerebrospinal fluid of Alzheimers disease subjects.","volume":"55","author":"Holsinger","year":"2004","journal-title":"Ann Neurol"},{"key":"R39-9-20210206","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/01.wnl.0000229925.52203.4c","article-title":"CSF BACE1 activity is increased in CJD and Alzheimer disease versus corrected other dementias.","volume":"67","author":"Holsinger","year":"2006","journal-title":"Neurology"},{"key":"R40-9-20210206","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1373\/clinchem.2006.066720","article-title":"Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay.","volume":"52","author":"Verheijen","year":"2006","journal-title":"Clin Chem"},{"key":"R41-9-20210206","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/archneur.65.8.1102","article-title":"Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.","volume":"65","author":"Zetterberg","year":"2008","journal-title":"Arch Neurol"},{"key":"R42-9-20210206","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3233\/JAD-2010-1367","article-title":"BACE1 activity in cerebrospinal fluid and its relation to markers of Alzheimers disease pathology.","volume":"20","author":"Mulder","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"R43-9-20210206","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12017-012-8171-4","article-title":"Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimers disease.","volume":"14","author":"Rosen","year":"2012","journal-title":"Neuromolecular Med"},{"key":"R44-9-20210206","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/archpsyc.64.6.718","article-title":"Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.","volume":"64","author":"Zhong","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"R45-9-20210206","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12017-012-8171-4","article-title":"Cerebrospinal fluid profiles of amyloid -related biomarkers in Alzheimers disease.","volume":"14","author":"Perneczky","year":"2012","journal-title":"Neuromolecular Med"},{"key":"R46-9-20210206","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1212\/WNL.0b013e318221ad47","article-title":"CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease.","volume":"77","author":"Lewczuk","year":"2011","journal-title":"Neurology"},{"key":"R47-9-20210206","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/mp.2008.84","article-title":"Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimers disease: a multicenter study.","volume":"15","author":"Gabelle","year":"2010","journal-title":"Mol Psychiatry"},{"key":"R48-9-20210206","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.brainres.2010.08.022","article-title":"Correlations between soluble alphabeta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid.","volume":"1357","author":"Lewczuk","year":"2010","journal-title":"Brain Res"},{"key":"R49-9-20210206","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JAD-2011-110857","article-title":"Cerebrospinal fluid soluble amyloid-beta protein precursor as a potential novel biomarkers of Alzheimers disease.","volume":"28","author":"Walsh","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"R50-9-20210206","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.","volume":"416","author":"Zempel","year":"2002","journal-title":"Nature"},{"key":"R51-9-20210206","doi-asserted-by":"crossref","first-page":"11938","DOI":"10.1523\/JNEUROSCI.2357-10.2010","article-title":"Abeta oligomers cause localized Ca(2) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines.","volume":"30","author":"Jin","year":"2010","journal-title":"J Neurosci"},{"key":"R52-9-20210206","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1073\/pnas.1017033108","article-title":"Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.","volume":"108","author":"De Felice","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R53-9-20210206","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.neurobiolaging.2007.02.029","article-title":"Alzheimers disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.","volume":"29","author":"Bruggink","year":"2008","journal-title":"Neurobiol Aging"},{"key":"R54-9-20210206","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimers isolated directly from Alzheimers brains impair synaptic plasticity and memory.","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat Med"},{"key":"R55-9-20210206","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1096\/fj.09-150359","article-title":"High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.","volume":"24","author":"Fukumoto","year":"2010","journal-title":"FASEB J"},{"key":"R56-9-20210206","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1073\/pnas.0409336102","article-title":"Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimers disease.","volume":"102","author":"Georganopoulou","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R57-9-20210206","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/nm0798-832","article-title":"Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimers patients by fluorescence correlation spectroscopy.","volume":"4","author":"Pitschke","year":"1998","journal-title":"Nat Med"},{"key":"R58-9-20210206","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ab.2012.09.014","article-title":"Amyloid-beta oligomer detection by enzyme-linked immunosorbent assay in cerebrospinal fluid and brain tissue.","volume":"433","author":"Bruggink","year":"2013","journal-title":"Anal Biochem"},{"key":"R59-9-20210206","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/JAD-2012-111361","article-title":"Amyloid-beta oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimers disease.","volume":"29","author":"Santos","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"R60-9-20210206","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic Abeta oligomer and Alzheimers disease: an emperor in need of clothes.","volume":"15","author":"Benilova","year":"2012","journal-title":"Nat Neurosci"},{"key":"R61-9-20210206","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimers disease.","volume":"362","author":"Querfurth","year":"2010","journal-title":"N Engl J Med"},{"key":"R62-9-20210206","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0896-6273(02)00794-8","article-title":"Inflammation in neurodegenerative disease: a double-edged sword.","volume":"35","author":"Wyss-Coray","year":"2002","journal-title":"Neuron"},{"key":"R63-9-20210206","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/bmm.09.89","article-title":"Biomarkers of oxidative damage and inflammation in Alzheimers disease.","volume":"4","author":"Galasko","year":"2010","journal-title":"Biomark Med"},{"key":"R64-9-20210206","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.biopsych.2010.06.012","article-title":"A meta-analysis of cytokines in Alzheimers disease.","volume":"68","author":"Swardfager","year":"2010","journal-title":"Biol Psychiatry"},{"key":"R65-9-20210206","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3233\/JAD-2010-1309","article-title":"Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimers disease and its levels correlate with cognitive decline.","volume":"19","author":"Comi","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"R66-9-20210206","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1096\/fj.11-202457","article-title":"Lipocalin 2: novel component of proinflammatory signaling in Alzheimers disease.","volume":"26","author":"Naude","year":"2012","journal-title":"FASEB J"},{"key":"R67-9-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2011.00001","article-title":"Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases.","volume":"3","author":"Rosen","year":"2011","journal-title":"Front Aging Neurosci"},{"key":"R68-9-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7827(97)00001-5","article-title":"The isoprostanes: unique bioactive products of lipid peroxidation.","volume":"36","author":"Morrow","year":"1997","journal-title":"Prog Lipid Res"},{"key":"R69-9-20210206","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1212\/WNL.52.3.562","article-title":"Increased CSF F2-isoprostane concentration in probable Alzheimers disease.","volume":"52","author":"Montine","year":"1999","journal-title":"Neurology"},{"key":"R70-9-20210206","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9","article-title":"Increased 8,12-iso-iPF2alpha-VI in Alzheimers disease: correlation of a noninvasive index of lipid peroxidation with disease severity.","volume":"48","author":"Pratico","year":"2000","journal-title":"Ann Neurol"},{"key":"R71-9-20210206","doi-asserted-by":"crossref","first-page":"510","DOI":"10.5858\/2001-125-0510-CFATAF","article-title":"Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls.","volume":"125","author":"Montine","year":"2001","journal-title":"Arch Pathol Lab Med"},{"key":"R72-9-20210206","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fphar.2012.00014","article-title":"Microglia function in Alzheimers disease.","volume":"3","author":"Solito","year":"2012","journal-title":"Front Pharmacol"},{"key":"R73-9-20210206","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimers disease.","volume":"368","author":"Jonsson","year":"2013","journal-title":"N Engl J Med"},{"key":"R74-9-20210206","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimers disease.","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"key":"R75-9-20210206","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1432-1327.1998.2510504.x","article-title":"Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages.","volume":"251","author":"Renkema","year":"1998","journal-title":"Eur J Biochem"},{"key":"R76-9-20210206","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.","volume":"93","author":"Hollak","year":"1994","journal-title":"J Clin Invest"},{"key":"R77-9-20210206","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12017-011-8147-9","article-title":"Cerebrospinal fluid microglial markers in Alzheimers disease: elevated chitotriosidase activity but lack of diagnostic utility.","volume":"13","author":"Mattsson","year":"2011","journal-title":"Neuromolecular Med"},{"key":"R78-9-20210206","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1212\/WNL.0b013e318247caa1","article-title":"Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease.","volume":"78","author":"Watabe-Rudolph","year":"2012","journal-title":"Neurology"},{"key":"R79-9-20210206","doi-asserted-by":"crossref","first-page":"25803","DOI":"10.1016\/S0021-9258(19)74461-5","article-title":"Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family.","volume":"268","author":"Hakala","year":"1993","journal-title":"J Biol Chem"},{"key":"R80-9-20210206","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","article-title":"YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimers disease.","volume":"68","author":"Craig-Schapiro","year":"2010","journal-title":"Biol Psychiatry"},{"key":"R81-9-20210206","doi-asserted-by":"crossref","first-page":"e16032","DOI":"10.1371\/journal.pone.0016032","article-title":"Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimers disease.","volume":"6","author":"Perrin","year":"2011","journal-title":"PLoS One"},{"key":"R82-9-20210206","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1750-3639.2008.00188.x","article-title":"Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimers disease.","volume":"19","author":"Sokolova","year":"2009","journal-title":"Brain Pathol"},{"key":"R83-9-20210206","doi-asserted-by":"crossref","first-page":"e30525","DOI":"10.1371\/journal.pone.0030525","article-title":"CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimers disease.","volume":"7","author":"Westin","year":"2012","journal-title":"PLoS One"},{"key":"R84-9-20210206","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1590\/S0004-282X2011000400009","article-title":"Chemokines in CSF of Alzheimers disease patients.","volume":"69","author":"Correa","year":"2011","journal-title":"Arq Neuropsiquiatr"},{"key":"R85-9-20210206","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1212\/01.wnl.0000191324.08289.9d","article-title":"Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration.","volume":"66","author":"Galimberti","year":"2006","journal-title":"Neurology"},{"key":"R86-9-20210206","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archneur.63.4.538","article-title":"Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.","volume":"63","author":"Galimberti","year":"2006","journal-title":"Arch Neurol"},{"key":"R87-9-20210206","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000089137","article-title":"Measurement of thirteen biological markers in CSF of patients with Alzheimers disease and other dementias.","volume":"21","author":"Blasko","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R88-9-20210206","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in Alzheimers disease: synapse loss is the major correlate of cognitive impairment.","volume":"30","author":"Terry","year":"1991","journal-title":"Ann Neurol"},{"key":"R89-9-20210206","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/(SICI)1522-2683(19990301)20:3<431::AID-ELPS431>3.0.CO;2-2","article-title":"Identification of synaptic vesicle, pre and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing.","volume":"20","author":"Davidsson","year":"1999","journal-title":"Electrophoresis"},{"key":"R90-9-20210206","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","article-title":"Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimers disease.","volume":"1362","author":"Thorsell","year":"2010","journal-title":"Brain Res"},{"key":"R91-9-20210206","doi-asserted-by":"crossref","first-page":"a006221","DOI":"10.1101\/cshperspect.a006221","article-title":"Fluid biomarkers in Alzheimer disease.","volume":"2","author":"Blennow","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R92-9-20210206","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/YCO.0b013e3282fc989f","article-title":"Plasma biomarkers of Alzheimers disease.","volume":"21","author":"Kawarabayashi","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"R93-9-20210206","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/bbrc.1995.2103","article-title":"Platelets are the primary source of amyloid beta-peptide in human blood.","volume":"213","author":"Chen","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"R94-9-20210206","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/archneurol.2012.1282","article-title":"Blood-based protein biomarkers for diagnosis of Alzheimer disease.","volume":"69","author":"Doecke","year":"2012","journal-title":"Arch Neurol"},{"key":"R95-9-20210206","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","article-title":"Classification and prediction of clinical Alzheimers diagnosis based on plasma signaling proteins.","volume":"13","author":"Ray","year":"2007","journal-title":"Nat Med"},{"key":"R96-9-20210206","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1212\/WNL.0b013e318266fa70","article-title":"Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease.","volume":"79","author":"Hu","year":"2012","journal-title":"Neurology"},{"key":"R97-9-20210206","doi-asserted-by":"crossref","first-page":"e29868","DOI":"10.1371\/journal.pone.0029868","article-title":"Evaluation of a previously suggested plasma biomarker panel to identify Alzheimers disease.","volume":"7","author":"Bjorkqvist","year":"2012","journal-title":"PLoS One"},{"key":"R98-9-20210206","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1749-6632.2009.05066.x","article-title":"Identifying early markers of Alzheimers disease using quantitative multiplex proteomic immunoassay panels.","volume":"1180","author":"Soares","year":"2009","journal-title":"Ann N Y Acad Sci"}],"container-title":["Current Opinion in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/YCO.0b013e32835f6747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:47:35Z","timestamp":1620978455000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001504-201305000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/yco.0b013e32835f6747","relation":{},"ISSN":["0951-7367"],"issn-type":[{"value":"0951-7367","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}